Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors

Abstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with...

Full description

Bibliographic Details
Main Authors: Christina Darden, Mark Price, David Ray, Grace Goldstein, Diana Goss, Lee Bennett, Diana Garbinsky, Ramya Thota
Format: Article
Language:English
Published: SpringerOpen 2021-09-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Online Access:https://doi.org/10.1186/s41687-021-00355-5
id doaj-7a5bb3f3059146f4bb5221529e84bf10
record_format Article
spelling doaj-7a5bb3f3059146f4bb5221529e84bf102021-09-12T11:31:03ZengSpringerOpenJournal of Patient-Reported Outcomes2509-80202021-09-015111010.1186/s41687-021-00355-5Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumorsChristina Darden0Mark Price1David Ray2Grace Goldstein3Diana Goss4Lee Bennett5Diana Garbinsky6Ramya Thota7Department of Surveys and Observational Studies, RTI Health SolutionsDepartment of Surveys and Observational Studies, RTI Health SolutionsIpsen Biopharmaceuticals, Inc.Carcinoid Cancer FoundationDepartment of Patient-Reported Outcomes, RTI Health SolutionsDepartment of Biometrics, RTI Health SolutionsDepartment of Biometrics, RTI Health SolutionsIntermountain Medical CenterAbstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with receiving LA SSA injections. Methods We conducted a serial survey, informed by qualitative interviews with eight patients treated with LA SSAs and two nurses who administer LA SSA injections, among patients undergoing LA SSA treatment over a 28-day period (administered at baseline and 14 days and 28 days after injection). Eligible patients, recruited by the Carcinoid Cancer Foundation, self-reported having received an LA SSA injection for physician-diagnosed NET within the 5 days before the survey. Results 202 patients completed the survey at baseline (82 receiving lanreotide and 120 receiving octreotide), 148 at day 14, and 124 at day 28. Patients reported consistently high satisfaction levels with their most recent LA SSA injection (91.1% at baseline, 85.1% at day 14, and 85.5% at day 28); 68.8% reported that their injection experience differed based on the nursing staff administering the injection. Conclusions Satisfaction with LA SSA injections is high among patients in this population, and specific experiences with LA SSA injections varied based on the nursing staff administering the injection. Evaluations of patients’ experiences and satisfaction with treatment are increasingly important as patients take more active roles in decision-making for their treatment pathways.https://doi.org/10.1186/s41687-021-00355-5Neuroendocrine tumorSerial surveyPatient experienceSatisfactionInterviewsSomatostatin analog
collection DOAJ
language English
format Article
sources DOAJ
author Christina Darden
Mark Price
David Ray
Grace Goldstein
Diana Goss
Lee Bennett
Diana Garbinsky
Ramya Thota
spellingShingle Christina Darden
Mark Price
David Ray
Grace Goldstein
Diana Goss
Lee Bennett
Diana Garbinsky
Ramya Thota
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Journal of Patient-Reported Outcomes
Neuroendocrine tumor
Serial survey
Patient experience
Satisfaction
Interviews
Somatostatin analog
author_facet Christina Darden
Mark Price
David Ray
Grace Goldstein
Diana Goss
Lee Bennett
Diana Garbinsky
Ramya Thota
author_sort Christina Darden
title Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
title_short Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
title_full Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
title_fullStr Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
title_full_unstemmed Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
title_sort patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
publisher SpringerOpen
series Journal of Patient-Reported Outcomes
issn 2509-8020
publishDate 2021-09-01
description Abstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with receiving LA SSA injections. Methods We conducted a serial survey, informed by qualitative interviews with eight patients treated with LA SSAs and two nurses who administer LA SSA injections, among patients undergoing LA SSA treatment over a 28-day period (administered at baseline and 14 days and 28 days after injection). Eligible patients, recruited by the Carcinoid Cancer Foundation, self-reported having received an LA SSA injection for physician-diagnosed NET within the 5 days before the survey. Results 202 patients completed the survey at baseline (82 receiving lanreotide and 120 receiving octreotide), 148 at day 14, and 124 at day 28. Patients reported consistently high satisfaction levels with their most recent LA SSA injection (91.1% at baseline, 85.1% at day 14, and 85.5% at day 28); 68.8% reported that their injection experience differed based on the nursing staff administering the injection. Conclusions Satisfaction with LA SSA injections is high among patients in this population, and specific experiences with LA SSA injections varied based on the nursing staff administering the injection. Evaluations of patients’ experiences and satisfaction with treatment are increasingly important as patients take more active roles in decision-making for their treatment pathways.
topic Neuroendocrine tumor
Serial survey
Patient experience
Satisfaction
Interviews
Somatostatin analog
url https://doi.org/10.1186/s41687-021-00355-5
work_keys_str_mv AT christinadarden patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
AT markprice patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
AT davidray patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
AT gracegoldstein patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
AT dianagoss patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
AT leebennett patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
AT dianagarbinsky patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
AT ramyathota patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors
_version_ 1717755601284497408